2025
SJR Q1
JCR Q1 · 5
158 matched articles
SCIE
Journal detail
International Journal of Antimicrobial Agents
- Publisher
- Elsevier B.V.
- Country
- Netherlands · Western Europe
- Type
- journal
- ISSN
-
0924857918727913
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,301
- Quartile Q1
- H-Index 167
- Cites/doc 4,29
- Docs (3y) 749
- Cites (3y) 3.340
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 5
- 5Y JIF 4,9
- JCI 1,24
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Infectious Diseases Q1
- Medicine (miscellaneous) Q1
- Microbiology (medical) Q1
- Pharmacology (medical) Q1
Areas
- Medicine
WoS categories
- Infectious Diseases | Microbiology | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,301 | 5 | 4,9 | 1,24 | Q1 | 167 |
| 2024 | Q1 | Q1 | 0,955 | 4,6 | 5 | 1,31 | Q1 | 161 |
| 2023 | Q1 | Q1 | 1,072 | 4,9 | 5,6 | 2,43 | Q1 | 161 |
| 2022 | Q1 | Q1 | 1,297 | 10,8 | 7,2 | 2,56 | Q1 | 161 |
| 2021 | Q1 | Q1 | 2,121 | 15,4 | 9,7 | 2,92 | Q1 | 161 |
| 2020 | Q1 | Q1 | 1,454 | 5,3 | 5,2 | 1,27 | Q1 | 161 |
| 2019 | Q1 | Q1 | 1,509 | 4,6 | 4,7 | 1,32 | Q1 | 161 |
| 2018 | — | Q1 | — | 4,6 | 4,6 | 1,23 | Q1 | — |
| 2017 | Q1 | Q1 | 1,699 | 4,3 | 4,3 | 1,17 | Q1 | 161 |
| 2016 | Q1 | Q1 | 1,608 | 4,3 | 4,3 | — | — | 161 |
| 2015 | Q1 | Q1 | 1,703 | 4,1 | 4,3 | — | — | 161 |
| 2014 | Q1 | Q1 | 1,477 | 4,3 | 4,3 | — | — | 161 |
| 2013 | Q1 | Q1 | 1,706 | 4,3 | 4,1 | — | — | 161 |
| 2012 | Q1 | Q1 | 1,633 | 4,4 | 3,9 | — | — | 161 |
| 2011 | Q1 | Q1 | 1,388 | 4,1 | 3,6 | — | — | 161 |
| 2010 | Q1 | Q1 | 1,36 | 3,8 | 3,5 | — | — | 161 |
| 2009 | — | Q2 | — | 3 | 2,8 | — | — | — |
| 2008 | — | Q2 | — | 3,1 | 2,7 | — | — | — |
| 2007 | — | Q2 | — | 2,3 | 2,2 | — | — | — |
| 2006 | — | Q2 | — | 2,2 | — | — | — | — |
| 2005 | — | Q2 | — | 2,4 | — | — | — | — |
| 2004 | — | Q2 | — | 2,1 | — | — | — | — |
| 2003 | — | Q2 | — | 1,9 | — | — | — | — |
| 2002 | — | Q2 | — | 1,6 | — | — | — | — |
| 2001 | — | Q2 | — | 1,4 | — | — | — | — |
| 2000 | — | Q3 | — | 1,1 | — | — | — | — |
| 1999 | — | Q3 | — | 0,9 | — | — | — | — |
| 1998 | — | Q3 | — | 0,8 | — | — | — | — |
| 1997 | — | Q3 | — | 0,7 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 23/141 |
| 2025 | MICROBIOLOGY | SCIE | Q2 | Q1 | 47/167 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 70/356 |
| 2024 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 17/137 |
| 2024 | MICROBIOLOGY | SCIE | Q1 | Q1 | 34/163 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 57/352 |
| 2023 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 16/132 |
| 2023 | MICROBIOLOGY | SCIE | Q1 | Q1 | 32/161 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 46/354 |
| 2022 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 12/96 |
| 2022 | MICROBIOLOGY | SCIE | Q1 | Q1 | 15/135 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 11/278 |
| 2021 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 11/95 |
| 2021 | MICROBIOLOGY | SCIE | Q1 | Q1 | 11/137 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 7/279 |
| 2020 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 17/93 |
| 2020 | MICROBIOLOGY | SCIE | Q2 | Q1 | 35/136 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 53/276 |
| 2019 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 15/92 |
| 2019 | MICROBIOLOGY | SCIE | Q1 | Q1 | 31/136 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 39/271 |
| 2018 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 15/89 |
| 2018 | MICROBIOLOGY | SCIE | Q1 | Q1 | 29/133 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 32/267 |
| 2017 | INFECTIOUS DISEASES | SCIE | Q1 | Q1 | 18/88 |
| 2017 | MICROBIOLOGY | SCIE | Q1 | Q1 | 27/126 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 34/261 |
| 2016 | INFECTIOUS DISEASES | SCIE | Q1 | — | 14/84 |
| 2016 | MICROBIOLOGY | SCIE | Q1 | — | 23/125 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 35/257 |
| 2015 | INFECTIOUS DISEASES | SCIE | Q1 | — | 16/83 |
| 2015 | MICROBIOLOGY | SCIE | Q1 | — | 25/123 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 42/255 |
| 2014 | INFECTIOUS DISEASES | SCIE | Q1 | — | 14/78 |
| 2014 | MICROBIOLOGY | SCIE | Q1 | — | 21/119 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 34/255 |
| 2013 | INFECTIOUS DISEASES | SCIE | Q1 | — | 12/72 |
| 2013 | MICROBIOLOGY | SCIE | Q1 | — | 22/119 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 29/256 |
| 2012 | INFECTIOUS DISEASES | SCIE | Q1 | — | 12/70 |
| 2012 | MICROBIOLOGY | SCIE | Q1 | — | 25/116 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 34/261 |
| 2011 | INFECTIOUS DISEASES | SCIE | Q1 | — | 14/70 |
| 2011 | MICROBIOLOGY | SCIE | Q1 | — | 25/114 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 40/261 |
| 2010 | INFECTIOUS DISEASES | SCIE | Q1 | — | 14/58 |
| 2010 | MICROBIOLOGY | SCIE | Q1 | — | 23/107 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 49/252 |
| 2009 | INFECTIOUS DISEASES | SCIE | Q2 | — | 16/57 |
| 2009 | MICROBIOLOGY | SCIE | Q2 | — | 31/95 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 74/237 |
| 2008 | INFECTIOUS DISEASES | SCIE | Q2 | — | 17/51 |
| 2008 | MICROBIOLOGY | SCIE | Q2 | — | 26/91 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 66/219 |
| 2007 | INFECTIOUS DISEASES | SCIE | Q3 | — | 26/50 |
| 2007 | MICROBIOLOGY | SCIE | Q2 | — | 44/93 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 90/205 |
| 2006 | INFECTIOUS DISEASES | SCIE | Q3 | — | 28/47 |
| 2006 | MICROBIOLOGY | SCIE | Q3 | — | 45/89 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 90/199 |
| 2005 | INFECTIOUS DISEASES | SCIE | Q2 | — | 19/43 |
| 2005 | MICROBIOLOGY | SCIE | Q2 | — | 35/86 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 65/193 |
| 2004 | INFECTIOUS DISEASES | SCIE | Q3 | — | 22/41 |
| 2004 | MICROBIOLOGY | SCIE | Q2 | — | 39/84 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 75/187 |
| 2003 | INFECTIOUS DISEASES | SCIE | Q2 | — | 20/41 |
| 2003 | MICROBIOLOGY | SCIE | Q2 | — | 39/84 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 75/185 |
| 2002 | INFECTIOUS DISEASES | SCIE | Q3 | — | 24/38 |
| 2002 | MICROBIOLOGY | SCIE | Q3 | — | 45/82 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 90/188 |
| 2001 | INFECTIOUS DISEASES | SCIE | Q3 | — | 24/37 |
| 2001 | MICROBIOLOGY | SCIE | Q3 | — | 47/81 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 92/186 |
| 2000 | INFECTIOUS DISEASES | SCIE | Q4 | — | 28/36 |
| 2000 | MICROBIOLOGY | SCIE | Q3 | — | 50/83 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 105/181 |
| 1999 | MICROBIOLOGY | SCIE | Q3 | — | 54/79 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 107/175 |
| 1998 | MICROBIOLOGY | SCIE | Q3 | — | 56/81 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 106/178 |
| 1997 | MICROBIOLOGY | SCIE | Q4 | — | 56/73 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 116/157 |